TY - JOUR
T1 - Prostate cancer
T2 - PI-RADS version 2 helps preoperatively predict clinically significant cancers
AU - Park, Sung Yoon
AU - Jung, Dae Chul
AU - Oh, Young Taik
AU - Cho, Nam Hoon
AU - Choi, Young Deuk
AU - Rha, Koon Ho
AU - Hong, Sung Joon
AU - Han, Kyunghwa
N1 - Publisher Copyright:
© RSNA, 2016.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/7
Y1 - 2016/7
N2 - Purpose: To retrospectively analyze whether Prostate Imaging Reporting and Data System (PI-RADS) version 2 is helpful for the detection of clinically significant prostate cancer. Materials and Methods: Institutional review board approved this retrospective study. A total of 425 patients with prostate cancer who had undergone magnetic resonance (MR) imaging and radical prostatectomy were included. Preoperative parameters such as prostate-specific antigen, biopsy Gleason score, greatest percentage of the core, percentage of the positive core number, and score at PI-RADS version 2 with MR imaging were investigated. Two independent readers performed PI-RADS scoring. Clinically significant prostate cancer was defined as follows: (a) Gleason score of 7 or greater, (b) tumor volume of 0.5 cm3 or greater, or a (c) positive extracapsular extension or seminal vesicle invasion. The reference standard was based on review of surgical specimen. Logistic regression was conducted to determine which parameters are associated with the presence of clinically significant cancer. Interreader agreement (ie, score ?4 or not) was investigated by using k statistics. Results: At univariate analysis, all of the preoperative parameters were significant for clinically significant prostate cancer (P , .05). However, multivariate analysis revealed that PIRADS score was the only significant parameter for both readers (reader 1: odds ratio = 28.170, P = .002; reader 2: odds ratio = 5.474, P = .007). The interreader agreement was excellent for PI-RADS score of 4 or greater (weighted k = 0.801; 95% confidence interval: 0.737, 0.865). Conclusion: The use of PI-RADS version 2 may help preoperatively diagnose clinically significant prostate cancer.
AB - Purpose: To retrospectively analyze whether Prostate Imaging Reporting and Data System (PI-RADS) version 2 is helpful for the detection of clinically significant prostate cancer. Materials and Methods: Institutional review board approved this retrospective study. A total of 425 patients with prostate cancer who had undergone magnetic resonance (MR) imaging and radical prostatectomy were included. Preoperative parameters such as prostate-specific antigen, biopsy Gleason score, greatest percentage of the core, percentage of the positive core number, and score at PI-RADS version 2 with MR imaging were investigated. Two independent readers performed PI-RADS scoring. Clinically significant prostate cancer was defined as follows: (a) Gleason score of 7 or greater, (b) tumor volume of 0.5 cm3 or greater, or a (c) positive extracapsular extension or seminal vesicle invasion. The reference standard was based on review of surgical specimen. Logistic regression was conducted to determine which parameters are associated with the presence of clinically significant cancer. Interreader agreement (ie, score ?4 or not) was investigated by using k statistics. Results: At univariate analysis, all of the preoperative parameters were significant for clinically significant prostate cancer (P , .05). However, multivariate analysis revealed that PIRADS score was the only significant parameter for both readers (reader 1: odds ratio = 28.170, P = .002; reader 2: odds ratio = 5.474, P = .007). The interreader agreement was excellent for PI-RADS score of 4 or greater (weighted k = 0.801; 95% confidence interval: 0.737, 0.865). Conclusion: The use of PI-RADS version 2 may help preoperatively diagnose clinically significant prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84975291051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975291051&partnerID=8YFLogxK
U2 - 10.1148/radiol.16151133
DO - 10.1148/radiol.16151133
M3 - Article
C2 - 26836049
AN - SCOPUS:84975291051
VL - 280
SP - 108
EP - 116
JO - Radiology
JF - Radiology
SN - 0033-8419
IS - 1
ER -